12Protecting the Cochlea with Drugs

FWhy drugs, and what they target

Insertion trauma and the implanted array trigger inflammation, hair-cell and neural apoptosis, and a fibro-osseous reaction that together erode residual hearing over weeks to months. Glucocorticoids (dexamethasone above all) blunt this inflammatory and fibrotic response and are the most studied otoprotective drug class around CI surgery. Reducing intracochlear fibrosis also keeps electrode impedances lower over time, an additional functional dividend (cross-referenced with impedance widgets elsewhere). Drugs complement - never replace - soft surgery (Module 10) and atraumatic arrays (Module 11).[2008][2010][2014]

TRoutes and timing of glucocorticoids

Systemic (IV/oral) steroids are simple but expose the patient to whole-body effects to reach a tiny target; intratympanic delivery concentrates drug at the round window with fewer systemic effects. Topical/intracochlear delivery (drug bathing the round window or eluted from the array) achieves the highest local cochlear concentrations. Timing matters: pre-operative dosing primes the cochlea before the insult; round-window dexamethasone is detectable in the cochlea for about 24 hours and protects most during difficult insertions. Intracochlear distribution differs by route, which helps explain why local delivery can outperform systemic at the cochlea.[2008][2012][2017]

CThe evidence: encouraging but mixed

Animal models consistently show dexamethasone protects residual hearing and reduces foreign-body fibrosis, with the largest benefit in technically difficult insertions. Clinical studies of preoperative intratympanic glucocorticoids report improved and more stable hearing preservation in round-window CI. Randomised trials of systemic steroids show benefit that is often modest and mainly short-term, so steroid use is supported but not a guaranteed rescue. Meta-analysis lists steroid use among the modifiable factors predicting better low-frequency preservation.[2010][2012][2017][2014]

CBeyond steroids: the emerging pipeline

Anti-apoptotic and anti-oxidant agents (and neurotrophins) are under study to rescue hair cells and neurons from the post-insertion stress cascade. Drug-eluting arrays carry dexamethasone on the electrode itself, delivering sustained local drug for weeks - reducing fibrous-tissue growth and impedance rise (detailed in the Emerging Tech chapter on drug-eluting and next-gen arrays). Convergence is the theme: technique, array geometry and pharmacology are merging into a single integrated otoprotective strategy. Local, sustained, low-dose delivery is the direction of travel - matching drug exposure to the timeline of the cochlear injury response.[2016][2010][2014]